Glucotrack, Inc.(GCTK)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 13 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
GCTK Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Glucotrack, Inc. (GCTK), a Healthcare sector company. GCTK is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 13 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), Glucotrack, Inc. reports net income of $-4.3M, free cash flow of $-4.0M. Top institutional holders of GCTK by reported 13-F value include GEODE CAPITAL MANAGEMENT,, Ikarian Capital,, BOOTHBAY FUND MANAGEMENT,, based on the most recent SEC filings. GCTK trades on the Nasdaq exchange and files with the SEC under CIK 1506983. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GCTK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Glucotrack, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-4.3M
Free Cash Flow
Q1 2026
$-4.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
+14.2% YoYOperating Income
-10.6% YoYEPS (Diluted)
-75.8% YoYTotal Assets
+32.1% YoYOp. Cash Flow
-22.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-19.4M +14.2% | $-22.6M -218.4% | $-7.1M -60.0% | $-4.4M -9.0% | $-4.1M -50.9% | $-2.7M |
| Operating Income | $-16.1M -10.6% | $-14.5M -104.8% | $-7.1M -60.3% | $-4.4M -9.7% | $-4.0M -29.0% | $-3.1M |
| EPS (Diluted) | $31.22 -75.8% | $129.12 +11913.4% | $1.07 +270.6% | $0.29 +11.5% | $0.26 +36.8% | $0.19 |
| Total Assets | $7.8M +32.1% | $5.9M +20.9% | $4.9M +101.2% | $2.4M -61.1% | $6.3M -40.9% | $10.6M |
| Operating Cash Flow | $-15.2M -22.0% | $-12.5M -90.5% | $-6.6M -75.9% | $-3.7M +1.1% | $-3.8M -7.7% | $-3.5M |
AI Insight: GCTK Financial Trends
Glucotrack remains unprofitable with no revenue reported; losses stable but equity deteriorating into Q1 2026.
• Net income losses narrowed from $10M in Q4 2024 to $4M in Q1 2026, suggesting improved operational control.
• Operating cash flow consistently negative at $2M–$5M per quarter; no revenue disclosed across all eight quarters.
• Equity swung from negative $13M (Q4 2024) to positive $7M (Q1–Q2 2025), but eroded back to negative $1M by Q1 2026.
⚠ No revenue visibility across entire dataset; company burning cash continuously with no disclosed commercial traction.
⚠ Equity position collapsed to negative $1M in latest quarter after brief recovery—solvency risk escalating.
AI Insight: GCTK Ratio Trends
Insufficient data: all ratio fields are empty across the entire period.
• No financial metrics available for analysis across Q2 2024 through Q1 2026.
⚠ Data completeness required before trend assessment is possible.
Get alerted when GCTK's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Glucotrack, Inc. including:
Top Institutional Holders of GCTK
GEODE CAPITAL MANAGEMENT, LLC
$30.6K47,001 shIkarian Capital, LLC
$29.8K45,830 shBOOTHBAY FUND MANAGEMENT, LLC
$8.8K13,525 shVANGUARD FIDUCIARY TRUST CO
$3.1K4,722 shALERUS FINANCIAL NA
$2.6K4,000 shTower Research Capital LLC (TRC)
$2.2K3,442 shUBS Group AG
$456.00702 shHRT FINANCIAL LP
$26.0040,631 shNewbridge Financial Services Group, Inc.
$22.0034 shSBI Securities Co., Ltd.
$6.009 sh
| Fund | Value | Shares |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | $30.6K | 47,001 |
| Ikarian Capital, LLC | $29.8K | 45,830 |
| BOOTHBAY FUND MANAGEMENT, LLC | $8.8K | 13,525 |
| VANGUARD FIDUCIARY TRUST CO | $3.1K | 4,722 |
| ALERUS FINANCIAL NA | $2.6K | 4,000 |
| Tower Research Capital LLC (TRC) | $2.2K | 3,442 |
| UBS Group AG | $456.00 | 702 |
| HRT FINANCIAL LP | $26.00 | 40,631 |
| Newbridge Financial Services Group, Inc. | $22.00 | 34 |
| SBI Securities Co., Ltd. | $6.00 | 9 |
More Healthcare Companies
View all Healthcare →Put GCTK on your watchlist
Track score changes the day Glucotrack, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is GCTK a good stock to buy?
13F Pro's AI-powered analysis of Glucotrack, Inc. (GCTK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GCTK are available on the GCTK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own GCTK?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GCTK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Glucotrack, Inc.'s investment landscape.